| ROCHE GS | 269.40 / -0.46% |
| Date/Time | 03/22 / 17:30 |
| Chg. / Chg.(%) | -1.25 / -0.46% |
| Bid | 268.75 / 275 |
| Ask | 269.20 / 10 |
| Open | 270.95 |
| Previous Close | 270.65 |
| High | 272.20 |
| Low | 268.40 |
| Volume [CHF] | 342,267,063.30 |
| Volume [Units] | 1,306,265 |
| Price fixings | 10189 |
| ISIN | CH0012032048 |
| Security | ROG |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 238.232 |  |
|
| SIX Swiss Ex.. | 269.40 | |
1,306,265 |
| Cboe Europe .. | 266.80 |  |
128,764 |
| London Inter.. | 270.45 | |
111,047 |
| Turquoise | 268.95 | |
96,337 |
| Xetra | 239.60 |  |
4,636 |
| TradeGate | 239.750 | |
1,524 |
| Frankfurt | 240.300 | |
1,418 |
| München | 239.60 | |
286 |
| Mexico | 5,153.43 | |
286 |
| Nasdaq Other.. | 271.7600 | |
138 |
| Hamburg | 240.30 | |
110 |
| Berlin | 239.90 | |
70 |
| Stuttgart | 239.900 | |
50 |
| Borsa Italia.. | 241.30 | |
20 |
| Düsseldorf | 239.50 | |
8 |
| gettex | 239.850 | |
|
| Mexico | 4,744.44 | 32 | |
| Borsa Italia.. | 241.30 | ||
| EUREX | Options | ||
News
- Biopharmaceuticals Market Analysis & Outlook, 2019 to 2024 - Their Ability to Treat Previously Untreatable Diseases is Spurring Growth
03/20/2019 / 12:40 - GlobeNewswire - FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
03/19/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
03/15/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
03/14/2019 / 07:00 - GlobeNewswire - Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
03/11/2019 / 07:03 - GlobeNewswire
Real-time